美国决定开始与古巴关系正常化的好处可能是美国人的新的突破性药物的介绍。古巴取得了引人注目的进步在预防医学领域。具体来说，加勒比海国家的研究人员已经开发出一种治疗性疫苗，延长肺癌患者的生命——美国最致命的癌症。药物cimavax自2011已提供给古巴公民。四月，罗斯威尔 水牛公园癌症中心，纽约签署了与古巴分子免疫学中心协议(CIM)开发一种疫苗的美国人在美国临床试验。

　　它其实是很便宜的，它的成本只是1美元，古巴政府最新开始的是自由古巴患者。当然，目前仍不清楚有多少美国患者最终支付应cimavax在美国面市研究表明，该药对那些对其他治疗无效的患者也有效。2008试验cimavax表明谁接受疫苗治疗的患者平均生存时间四至六个月。

　　不过，作为有线的注释，它没有特效的治疗方法。cimavax防止肺肿瘤生长和转移，使病人的健康生活时间更长。而cimavax肺癌疫苗是第一个出来的分子免疫学的25年的研究中心，该中心自创建了第二个肺癌疫苗，显示了平等的承诺。批准的2013，racotumomab也出现显着阻断他们的肿瘤生长延长肺癌患者的生命。

　　原文

　　Cuba offers US its breakthrough lung cancer vaccine as relations normalize with communist nation

　　One of the benefits of the U.S. decision to begin to normalize relations with Cuba could be the introduction of new breakthrough medicines for Americans.

　　Cuba made impressive advancements in the field of preventative medicine during the five decade rift with the US. Specifically, researchers in the Caribbean nation have developed a therapeutic vaccine that extends the life of patients suffering from lung cancer--America's most deadly cancer.

　　The drug Cimavax has been available to Cuban citizens since 2011. In April, Roswell Park Cancer Center of Buffalo, New York signed an agreement with Cuba's Center for Molecular Immunology (CIM) to develop a the vaccine for Americans with a clinical trial in the United States.

　　'The chance to evaluate a vaccine like this is a very exciting prospect,' says Candace Johnson, CEO of Roswell Park.

　　She told Wired her excitement stems from the vaccine's relatively low toxicity and low cost to produce and store.

　　It's so cheap, in fact, that it costs the Cuban government just $1 per shot and is free to Cuban patients. Of course, it remained unclear how much American patients would eventually pay should Cimavax reach the market in the U.S.

　　Research shows that the drug is also effective for patients who've not responded to other treatments. A 2008 trial of Cimavax showed patients who received the vaccine lived on average four to six months longer.

　　Though, as Wired notes, it's no miracle cure. Cimavax prevents lung tumors from growing and metastasizing further, allowing sufferers to live healthier lives longer.

　　While Cimavax was the first lung vaccine to come out of the Center for Molecular Immunology's 25 years of research, the center has since created a second lung cancer vaccine that shows equal promise.

　　Approved in 2013, Racotumomab also appears to significantly extend the life of lung cancer patients by halting the growth of their tumors.

　　Like in the U.S., lung cancer is the most deadly cancer in Cuba, where some 5,000 residents had an advanced form of the disease at the time of Racotumomab's approval.